This treatment option can be used as primary and secondary prevention
Community protocols then increase to 0.5 mg 3x weekly (1.5 mg total weekly) when well-tolerated
This mechanism would bypass the gastrointestinal tract and provide steady-state drug levels over an extended period
Less adipose tissue means less circulating volume that the heart must pump, which lowers cardiac output and downstream pressure Lower sympathetic tone
Final Thoughts Most people lose 15 to 20 percent of their body weight on semaglutide over 12 to 18 months when combining the medication with healthy lifestyle changes
A plausible scenario, then, looks like this: Phase 3 primary completion in late 2025, NDA submission in the second half of 2025, FDA filing acceptance and review initiation in early 2026, and a PDUFA (Prescription Drug User Fee Act) action date likely in mid to late 2026